Companiesandmarkets.com: Depression Therapeutics Market To See Patent Expiries

LONDON--(BUSINESS WIRE)-- The global depression therapeutics market was worth $4.3 billion in 2010. It is expected to grow at a compound annual growth rate (CAGR) of 13.4% over the next eight years to reach $8 billion by 2018. The depression therapeutics market will witness the patent expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR in 2014. However, the launch of new drugs such as Viibryd, LuAA21004, Levomilnacipran (F2695) and AGO178 (in the US), offering better efficacy and safety profiles, along with disease modifying properties, will help to sustain steady and positive growth during the forecast period to 2018.

The market for depression therapeutics is well served by the current approved drug classes, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs). The depression therapeutics market will face the patent expiry of leading drugs such as Lexapro (2012), Cymbalta (2013) and Effexor XR (2014). However, the expected launch of Lu AA21004 by Lundbeck and Levomilnacipran (F2695) by Forest Laboratories in the US and EU5 in 2013 and the launch of AGO178 in the US in 2013 by Novartis, will help to maintain the positive growth trend during the forecast period.

H Lundbeck A/S, Novartis, Targacept Inc., AstraZeneca and Eli Lilly are going to be the future key players in the depression market. The existing market landscape remains competitive, because the treatment of depression relies on established therapies such as SSRIs, SNRIs and TCAs.

This report is an essential source of information and analysis on the global depression therapeutics market. The report identifies the key trends shaping and driving the global depression market. The report also provides insights in to the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.

Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.companiesandmarkets.com/r.ashx?id=HOZ783H88701726?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Paul Chapman
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Mental Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.